UpdatesPress Release
Epigral reported Q1FY27 PAT up 25% to ₹99 Cr, with revenue up 15% to ₹709 Cr.
Epigral LimitedEPIGRAL · Filed with the exchange
The board approved ₹600 Cr capex for a 1,25,000 TPA Epoxy Resin & Formulations plant and a Multi-Purpose Plant, targeting H2FY28 commissioning, leveraging internal raw materials.
No comments yet. Be the first.